A qualitative review of issues arising in the use of psychostimulant medications in patients with ADHD and co-morbid substance use disorders

Current Medical Research and Opinion

Volumn 24, Issue 5, 2008, Pages 1345-1357

  Kollins, Scott H ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Attention deficit disorder with hyperactivity; Central nervous system stimulants; Psychopharmacology; Substance related disorders

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; METHYLPHENIDATE; MIXED AMPHETAMINE SALT; PLACEBO; PSYCHOSTIMULANT AGENT;

ALCOHOLISM; ANXIETY; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; BIPOLAR DISORDER; CLINICAL TRIAL; COCAINE DEPENDENCE; COMORBIDITY; CONDUCT DISORDER; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISORIENTATION; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; EATING DISORDER; HEROIN DEPENDENCE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSOMNIA; LOW DRUG DOSE; PATIENT MONITORING; PSYCHOPATHY; PSYCHOPHARMACOTHERAPY; QUALITATIVE ANALYSIS; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; AGE DISTRIBUTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; PREDICTIVE VALUE OF TESTS; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 44349122955     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X280707     Document Type: Review

References (94)

1. Anon. Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder - United States, 2003. MMWR Morb Mortal Wkly Rep 2005;54:842-7
2. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-23
3. Faraone SV, Biederman J. Prevalence of adult ADHD in the United States. Presented at: 157th American Psychiatric Association Annual Meeting, May 1-6, 2004, New York (NY)
4. Biederman J, Mick E, Faraone SV, et al. Influence of gender on attention-deficit/hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 2002;159:36-42
5. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41:26S-49S
6. Anon. Methylphenidate: a background paper. United States Drug Enforcement Administration; 1995
7. Wilens TE, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006;45:408-14
8. Kollins SH. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J Clin Psychiatry 2003(64 Suppl);11:14-8
9. Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 2001;68:611-27
10. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 1986;396:157-98
11. Sax KW, Strakowski SM. Behavioral sensitization in humans. J Addict Dis 2001;20:55-65
12. Vitiello B. Long-term effects of stimulant medications on the brain: possible relevance to the treatment of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2001;11:25-34
13. Fredericks EM, Kollins SH. Assessing methylphenidate preference in ADHD patients using a choice procedure. Psychopharmacology (Berl) 2004;175:391-8
14. Fredericks EM, Kollins SH. A pilot study of methylphenidate preference assessment in children diagnosed with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2005;15:729-41
15. Flory K, Milich R, Lynam DR, et al. Relation between childhood disruptive behavior disorders and substance use and dependence symptoms in young adulthood: individuals with symptoms of attention-deficit/hyperactivity disorder and conduct disorder are uniquely at risk. Psychol Addict Behav 2003;17:151-8
16. Biederman J, Wilens T, Mick E, et al. Psychoactive substance use disorders in adults with attention-deficit/hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995;152:1652-8
17. McGough JJ, Smalley SL, McCracken JT, et al. Psychiatric comorbidity in adult attention-deficit/hyperactivity disorder: findings from multiplex families. Am J Psychiatry 2005;162:1621-7
18. Wilens TE, Biederman J, Mick E, et al. Attention-deficit/hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis 1997;185:475-82
19. Schubiner H, Tzelepis A, Milberger S, et al. Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry 2000;61:244-51
20. Carroll KM, Rounsaville BJ. History and significance of childhood attention-deficit disorder in treatment-seeking cocaine abusers. Compr Psychiatry 1993;34:75-82
21. Katusic SK, Barbaresi WJ, Colligan RC, et al. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol 2005;15:764-76
22. Mannuzza S, Klein RG, Bonagura N, et al. Hyperactive boys almost grown up. V. Replication of psychiatric status. Arch Gen Psychiatry 1991;48:77-83
23. Biederman J, Monuteaux MC, Mick E, et al. Young adult outcome of attention-deficit/hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med 2006;36:167-79
24. Gordon SM, Tulak F, Troncale J. Prevalence and characteristics of adolescent patients with co-occurring ADHD and substance dependence. J Addict Dis 2004;23:31-40
25. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1997;36:21-9
26. Barkley RA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1990;29:546-57
27. August GJ, Winters KC, Realmuto GM, et al. Prospective study of adolescent drug use among community samples of ADHD and non-ADHD participants. J Am Acad Child Adolesc Psychiatry 2006;45:824-32
28. Wilens TE, Biederman J, Millstein RB, et al. Risk for substance use disorders in youths with child- and adolescent-onset bipolar disorder. J Am Acad Child Adolesc Psychiatry 1999;38:680-5
29. Williams RJ, Goodale LA, Shay-Fiddler MA, et al. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents. Am J Addict 2004;13:381-9
30. Milberger S, Biederman J, Faraone SV, et al. Associations between ADHD and psychoactive substance use disorders. Findings from a longitudinal study of high-risk siblings of ADHD children. Am J Addict 1997;6:318-29
31. Neumark-Sztainer D, Story M, French S, et al. Patterns of health-compromising behaviors among Minnesota adolescents: sociodemographic variations. Am J Public Health 1996;86:1599-606
32. Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention-deficit/ hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics 2005;115:1734-46
33. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985;142:1259-64
34. Castaneda R, Lifshutz H, Galanter M, et al. Empirical assessment of the self-medication hypothesis among dually diagnosed inpatients. Compr Psychiatry 1994;35:180-4
35. Wilens TE. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am 2004;27:283-301
36. Levin ED, Conners CK, Sparrow E, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 1996;123:55-63
37. Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry 2005;62:1142-7
38. Fuemmeler BF, Kollins SH, McClernon FJ. Attention-deficit/hyperactivity disorder symptoms predict nicotine dependence and progression to regular smoking from adolescence to young adulthood. J Pediatr Psychol 2007;32:1203-13
39. Zametkin AJ, Liotta W. The neurobiology of attention-deficit/ hyperactivity disorder. J Clin Psychiatry 1998;59(Suppl 7):17-23
40. Schiffer WK, Volkow ND, Fowler JS, et al. Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse 2006;59:243-51
41. Volkow ND, Fowler JS, Wang GJ, et al. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol 2002;12:557-66
42. Rapoport JL, Buchsbaum MS, Weingartner H, et al. Dextroamphetamine. Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 1980;37:933-43
43. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988;85:5274-8
44. Koob GF, Nestler EJ. The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci 1997;9:482-97
45. Balster RL, Schuster CR. Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J Exp Anal Behav 1973;20:119-29
46. Resnick RB, Kestenbaum RS, Schwartz LK. Acute systemic effects of cocaine in man: a controlled study by intranasal and intravenous routes. Science 1977;195: 696-8
47. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995;52:456-63
48. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003;160:1909-18
49. Rush CR, Kollins SH, Pazzaglia PJ. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in D-amphetamine-trained humans. Exp Clin Psychopharmacol 1998;6:32-44
50. Coetzee M, Kaminer Y, Morales A. Megadose intranasal methylphenidate (Ritalin) abuse in adult attention-deficit/hyperactivity disorder. Subst Abuse 2002;23:165-9
51. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003;60:204-11
52. Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 2006;163:387-95
53. Kollins SH, Rush CR, Pazzaglia PJ, et al. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 1998;6:367-74
54. Volkow ND. Stimulant medications: how to minimize their reinforcing effects? Am J Psychiatry 2006;163:359-61
55. Johnston LD, O'Malley PM, Bachman JG, et al. Overall teen drug use continues gradual decline; but use of inhalants rises. http://www. monitoringthefuture.org/pressreleases/04drugpr.pdf [last accessed 12 March 2007]
56. Klein-Schwartz W, McGrath J. Poison centers' experience with methylphenidate abuse in pre-teens and adolescents. J Am Acad Child Adolesc Psychiatry 2003;42:288-94
57. Babcock Q, Byrne T. Student perceptions of methylphenidate abuse at a public liberal arts college. J Am Coll Health 2000;49:143-5
58. McCabe SE, Knight JR, Teter CJ, et al. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 2005;100:96-106
59. Forrester MB. Adderall abuse in Texas, 1998-2004. J Toxicol Environ Health A 2007;70:658-64
60. Anon. Results from the 2005 National Survey on Drug Use and Health: National Findings. Rockville (MD): Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2006
61. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use and diversion of prescription stimulant medication. J Psychoactive Drugs 2006;38:43-56
62. Teter CJ, McCabe SE, LaGrange K, et al. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 2006;26:1501-10
63. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use, and diversion of abusable prescription drugs. J Am Coll Health 2006;54:269-78
64. Ahmann PA, Waltonen SJ, Olson KA, et al. Placebo-controlled evaluation of Ritalin side effects. Pediatrics 1993;91:1101-6
65. Musser CJ, Ahmann PA, Theye FW, et al. Stimulant use and the potential for abuse in Wisconsin as reported by school administrators and longitudinally followed children. J Dev Behav Pediatr 1998;19:187-92
66. McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse 2004;39:1095-116
67. Barrett SP, Darredeau C, Bordy LE, et al. Characteristics of methylphenidate misuse in a university student sample. Can J Psychiatry 2005;50:457-61
68. Kadison R. Getting an edge - use of stimulants and antidepressants in college. New Engl J Med 2005;353:1089-91
69. Huss M, Lehmkuhl U. Methylphenidate and substance abuse: a review of pharmacology, animal, and clinical studies. J Atten Disord 2002;6(Suppl 1):S65-S71
70. Woolverton WL, Cervo L, Johanson CE. Effects of repeated methamphetamine administration on methamphetamine self-administration in rhesus monkeys. Pharmacol Biochem Behav 1984;21:737-41
71. Piazza PV, Deminiere JM, le Moal M, et al. Factors that predict individual vulnerability to amphetamine self-administration. Science 1989;245:1511-3
72. Piazza PV, Deminiere JM, le Moal M, et al. Stress- and pharmacologically-induced behavioral sensitization increases vulnerability to acquisition of amphetamine self-administration. Brain Res 1990;514:22-6
73. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 1998;31:533-44
74. Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999;104:e20
75. Mannuzza S, Klein RG, Moulton III JL. Does stimulant treatment place children at risk for adult substance abuse? A controlled, prospective follow-up study. J Child Adolesc Psychopharmacol 2003;13:273-82
76. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003;111:179-85
77. Faraone SV, Biederman J, Wilens TE, et al. A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults. Psychol Med 2007;37:1743-52
78. Mague SD, Andersen SL, Carlezon Jr WA. Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats. Biol Psychiatry 2005;57:120-5
79. Andersen SL, Arvanitogiannis A, Pliakas AM, et al. Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat Neurosci 2002;5:13-4
80. Brandon CL, Marinelli M, White FJ. Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons. Biol Psychiatry 2003;54:1338-44
81. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-901
82. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112-20
83. Lile JA, Stoops WW, Durell TM, et al. Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans. Exp Clin Psychopharmacol 2006;14:136-47
84. Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention-deficit/ hyperactivity disorder. Am J Psychiatry 1996;153:1147-53
85. Adler LA, Resnick S, Kunz M, et al. Open-label trial of venlafaxine in adults with attention-deficit disorder. Psychopharmacol Bull 1995;31:785-8
86. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 2005;57:793-801
87. Castaneda R, Levy R, Hardy M, et al. Long-acting stimulants for the treatment of attention-deficit disorder in cocaine-dependent adults. Psychiatr Serv 2000;51:169-71
88. Schubiner H, Saules KK, Arfken CL, et al. Double-blind, placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002;10:286-94
89. Wilens TE. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry 2004;65(Suppl 3):38-45
90. Levin FR, Evans SM, McDowell DM, et al. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry 1998;59:300-5
91. Mariani JJ, Levin FR. Treatment strategies for co-occurring ADHD and substance use disorders. Am J Addict 2007;16(Suppl 1):45-54
92. Upadhyaya HP. Managing ADHD in the presence of comorbid substance use disorder. J Clin Psychiatry 2007;68:e15
93. Carpentier PJ, de Jong CA, Dijkstra BA, et al. A controlled trial of methylphenidate in adults with attention-deficit/hyperactivity disorder and substance use disorders. Addiction 2005;100:1868-74
94. Schubiner H. Substance abuse in patients with attention-deficit/ hyperactivity disorder: therapeutic implications. CNS Drugs 2005;19:643-55